About Sentiss Pharma Private Limited
Data last updated:
Sentiss Pharma Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the medical and laboratory equipment segment of the healthcare sector. It was incorporated on 13 January 1994 and has been in existence for over 32 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U74899DL1994PTC056894. Its GSTIN is 07AAACP1612Q1ZC (Delhi). The company holds 16 GST registrations, of which 14 are active.
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹5.88 Cr. It was formerly known as Promed Exports Private Limited. It is led by directors including Deepak Bahri (Managing Director) and Canakapalli Bhaktavatasala Rao.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 212 Ashirwad Commercialcomplex D – I Green Park, New Delhi, Delhi, India – 110016.
As per the financials filed for FY 2025, the company reported a revenue of ₹1,262.74 Cr, a growth of 43% compared to the previous year. For the same year it recorded a net profit of ₹35.79 Cr (net margin 2.8%) and EBITDA of ₹213.97 Cr (EBITDA margin 16.9%). Revenue has grown at a compounded annual rate (CAGR) of 43% over three years and 24% over five years.
The company has about 689 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Sentiss Pharma. As per MCA filings, the company has open charges of ₹504.85 Cr and satisfied charges of ₹795.76 Cr on record. Court records list 39 cases involving the company, including 28 filed by the company and 11 filed against it; 13 cases are pending. The company has 7 deals on record (6 secondary share transfers, 1 funding round), with disclosed funding of ₹10 Lakh; the latest was in November 2018. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Synthimed Labs Private Limited with revenue of ₹1,478.44 Cr. The company has 16 MSME Form 1 returns on record between 2018 and 2024, listing 116 overdue payments to 42 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sentisspharma.com.
Company details
Contact details
Sentiss Pharma Private Limited's registered office is in New Delhi, Delhi. Its website is sentisspharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address212 Ashirwad Commercialcomplex D – I Green Park, New Delhi, Delhi, India – 110016
- IndustryHealthcare, Medical & Laboratory Equipment
To see the full contact details of Sentiss Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Sentiss Pharma operates one associated brand: Sentiss Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Develops and manufactures ophthalmic, inhalational, ENT, and specialty drugs worldwide. | sentisspharma.com |
Business activity
The main business activity of Sentiss Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Sentiss Pharma Private Limited, buy the company report.
Financials of Sentiss Pharma Private Limited
FY 2025 filings availableSentiss Pharma Private Limited reported revenue of ₹1,262.74 Cr (up 43% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 24% over five years, including 43% growth in the latest year. EBITDA rose 285% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹213.97 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹35.79 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 16.9% | ||||
| Net Profit Margin | 2.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Sentiss Pharma Private Limited, buy the company report.
Board of directors of Sentiss Pharma Private Limited
Sentiss Pharma has 6 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Canakapalli Bhaktavatasala Rao | Director | 29 Apr 2019 | 7 Years 5 Months | Current |
| Deepak Bahri | Managing Director | 01 May 1995 | 31 Years 5 Months | Current |
| Mahesh Kumar Garg | Director | 09 Jun 2015 | 11 Years 4 Months | Current |
| Geeta Mathur Also directs: Healthcare Global Enterprises Limited, Dixon Technologies (India) Limited, Ashok Leyland Limited and 5 more | Director | 17 Jul 2017 | 9 Years 3 Months | Current |
| Sameer Agarwal | Director | 10 Feb 2025 | 1 Years 8 Months | Current |
| Deepak Kumar Khungar | Director | 21 Nov 2024 | 1 Years 11 Months | Current |
Peer comparison
Sentiss Pharma Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Synthimed Labs Private Limited | ₹1,478.44 Cr (FY 2025) | 25706.0% | Chandigarh, India | |||
| Onesource Specialty Pharma Limited | ₹1,462.33 Cr (FY 2025) | 730.0% | Thane, Maharashtra, India | |||
| Par Formulations Private Limited | ₹1,462.09 Cr (FY 2025) | 5.0% | Chennai, Tamil Nadu, India | |||
| Encube Ethicals Private Limited | ₹1,369 Cr (FY 2025) | 25.0% | Mumbai, Maharashtra, India | |||
| Sentiss Pharma Private Limitedthis company | ₹1,262.74 Cr (FY 2025) | ₹35.79 Cr | 2.8% | 43.0% | 689 | New Delhi, Delhi, India |
| Innova Captab Limited | ₹1,255.72 Cr (FY 2025) | 15.0% | Thane, Maharashtra, India | |||
| Cipla Health Limited | ₹1,228.87 Cr (FY 2025) | 17.0% | Mumbai, Maharashtra, India | |||
| Neon Laboratories Limited | ₹1,222.81 Cr (FY 2025) | 4.0% | Mumbai, Maharashtra, India | |||
| Corona Remedies Limited | ₹1,202.35 Cr (FY 2025) | 18.0% | Ahmedabad, Gujarat, India |
To see the full peer comparison of Sentiss Pharma Private Limited, buy the company report.
Auditor
Sentiss Pharma Private Limited is audited by S.R. Batliboi & CO. LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S.R. Batliboi & CO. LLP | FY 2023 | 301003E/E300005 |
Shareholding
The shareholding of Sentiss Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Sentiss Pharma Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 25 Nov 2025 | 101191596 | Yes Bank Limited | ₹230.97 Cr | Open | |
| 15 Mar 2025 | 101076333 | Others | ₹20 Cr | Open | |
| 26 Nov 2024 | 101006068 | Others | ₹54.88 Cr | Open | |
| 28 Feb 2024 | 100886443 | Hdfc Bank Limited | ₹30 Cr | Open | |
| 23 Sep 2023 | 100796746 | Others | ₹50 Cr | Open |
To see the full charge records of Sentiss Pharma Private Limited, buy the company report.
Total charge records: 33 View all charges
Deals & funding
Sentiss Pharma Private Limited has 7 deals on record (6 secondary share transfers, 1 funding round), with disclosed funding of ₹10 Lakh; the latest was in November 2018.
Deals on record (5 of 7)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2018 | Secondary share transfer | Undisclosed | Seller: 2 individuals |
| Dec 2014 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: an individual |
| May 2014 | Secondary share transfer | Undisclosed | Buyer: Rubicon Securities Private Limited , 2 individuals Seller: an individual |
| Nov 2013 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Sidvim Lifesciences Private Limited |
| Jan 2009 | Funding round | ₹10 Lakh | Investors: Sidvim Lifesciences Private Limited , an individual |
To see the full deal history of Sentiss Pharma Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Sentiss Pharma Private Limited has 39 court cases on record: 28 filed by Sentiss Pharma, 11 filed against it. 13 cases are pending and 26 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 32 | 9 | 12 |
| High courts | 7 | 2 | 1 |
Cases on record (5 of 39)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Court case (O.M.P. (COMM)) | Filed against the company by Global Calcium Private Limited | Pending |
| District court, Gurugram, Haryana | Commercial suit | Filed by the company against Vedas Medisolutions Pvt Ltd and Anr and 1 other | Pending |
| Bombay High Court | Court case (CARAP) | Filed by the company against Indoco Remedies Limited | Disposed |
| High Court | Court case (CARAP) | Filed by the company against Indoco Remedies Limited | Disposed |
| High Court of Delhi | Arbitration matter | Filed by the company against Global Calcium Pvt. Ltd. | Disposed |
To see the full case history of Sentiss Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Sentiss Pharma Private Limited was last rated by Crisil on 30 Jun 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 30 Jun 2020 |
To see the full credit ratings and regulatory alerts of Sentiss Pharma Private Limited, buy the company report.
MSME payment delays
Sentiss Pharma Private Limited has 16 MSME Form 1 returns on record between 2018 and 2024, listing 116 overdue payments to 42 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 42)
To see the full MSME payment records of Sentiss Pharma Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Sentiss Pharma Private Limited has a workforce of 689 employees on its EPFO records as of Apr 06, 2024, across 2 active EPFO establishments.
GST
Sentiss Pharma has 16 GST registrations: 14 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAACP1612Q1ZC | Delhi | Active | 01 Jul 2017 |
| 02AAACP1612Q1ZM | Himachal Pradesh | Active | 01 Jul 2017 |
| 06AAACP1612Q1ZE | Haryana | Active | 01 Jul 2017 |
| 08AAACP1612Q1ZA | Rajasthan | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Sentiss Pharma Private Limited, buy the company report.
Recent activity
Sentiss Pharma Private Limited has 21 board changes on record since 1995: 6 appointments and 15 cessations. The latest: Deepak Kumar Khungar ceased to be Additional Director on 16 Mar 2025.
90 earlier events are in the company report.
Frequently asked questions
Sentiss Pharma is an active private limited company based in New Delhi, Delhi, India. The company works in medical and laboratory equipment, within the healthcare industry. It was incorporated on 13 January 1994 (32+ years old) and is registered under CIN U74899DL1994PTC056894.
Sentiss Pharma has 6 current directors:
- Deepak Bahri - Managing Director
- Canakapalli Bhaktavatasala Rao - Director
- Mahesh Kumar Garg - Director
- Geeta Mathur - Director
- Sameer Agarwal - Director
- Deepak Kumar Khungar - Director
The latest financial statements of Sentiss Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Sentiss Pharma is 07AAACP1612Q1ZC, registered in Delhi. The company has 16 GST registrations in all, of which 14 are active and 2 are cancelled or inactive. Other active GSTINs include 02AAACP1612Q1ZM (Himachal Pradesh), 06AAACP1612Q1ZE (Haryana), 08AAACP1612Q1ZA (Rajasthan).
The CIN (Corporate Identification Number) of Sentiss Pharma is U74899DL1994PTC056894. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Sentiss Pharma has 39 court cases on record: 28 filed by the company and 11 filed against it. 13 are pending. Most are in the district courts.
Sentiss Pharma was incorporated on 13 January 1994, making it 32+ years old. It is registered with the Registrar of Companies, Delhi.
Sentiss Pharma has 7 deals on record (6 secondary share transfers, 1 funding round), with disclosed funding of ₹10 Lakh; the latest was in November 2018.
The peers of Sentiss Pharma by revenue are Synthimed Labs Private Limited, Onesource Specialty Pharma Limited, Par Formulations Private Limited, Encube Ethicals Private Limited, Innova Captab Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Deepak Kumar Khungar ceased to be Additional Director on 16 Mar 2025. Sameer Agarwal ceased to be Additional Director on 16 Mar 2025. Sameer Agarwal was appointed as Director on 10 Feb 2025. Sentiss Pharma has 21 board changes on record in total.
Sentiss Pharma has 16 MSME Form 1 returns on record between 2018 and 2024, listing 116 overdue payments to 42 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Sentiss Pharma can be reached through the website sentisspharma.com. Its registered office is in New Delhi, Delhi, India.